Clinical trialNCT07517263RecruitingPhase 3Interventional

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

SponsorNovartis PharmaceuticalsEnrollment5,700Cardiovascular Disease and Lipoprotein(a)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

643 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Ramos Mejía, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
CABA, Buenos Aires F.D., Argentina
Recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Recruiting
Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, Argentina
Recruiting
Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, Argentina
Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Recruiting
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Recruiting
Novartis Investigative Site
Santa Fe, Santa Fe Province, Argentina
Recruiting
Novartis Investigative Site
Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Caba, Argentina
Recruiting
Novartis Investigative Site
Capital Federal, Argentina
Recruiting
Novartis Investigative Site
Corrientes, Argentina
Recruiting
Novartis Investigative Site
Córdoba, Argentina
Active, not recruiting
Novartis Investigative Site
San Luis, Argentina
Recruiting

Australia

Novartis Investigative Site
Camperdown, New South Wales, Australia
Recruiting
Novartis Investigative Site
Liverpool, New South Wales, Australia
Recruiting
Novartis Investigative Site
Chemside, Queensland, Australia
Recruiting
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Recruiting
Novartis Investigative Site
Clayton, Victoria, Australia
Recruiting
Novartis Investigative Site
Perth, Western Australia, Australia
Recruiting

Austria

Novartis Investigative Site
Graz, Austria
Active, not recruiting
Novartis Investigative Site
Innsbruck, Austria
Recruiting
Novartis Investigative Site
Linz, Austria
Active, not recruiting
Novartis Investigative Site
Salzburg, Austria
Active, not recruiting
Novartis Investigative Site
Vienna, Austria
Active, not recruiting
Novartis Investigative Site
Vienna, Austria
Active, not recruiting

Belgium

Novartis Investigative Site
Brussels, Brussels Capital, Belgium
Recruiting
Novartis Investigative Site
Genk, Limburg, Belgium
Active, not recruiting
Novartis Investigative Site
Aalst, Oost Vlaanderen, Belgium
Recruiting
Novartis Investigative Site
Kortrijk, West-Vlaanderen, Belgium
Active, not recruiting
Novartis Investigative Site
Bruges, Belgium
Active, not recruiting
Novartis Investigative Site
Dendermonde, Belgium
Recruiting
Novartis Investigative Site
Huy, Belgium
Recruiting
Novartis Investigative Site
Mechelen, Belgium
Recruiting

Brazil

Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Recruiting
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Recruiting

603 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pelacarsen

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 May 2026
Primary completion: 9 Jan 2030
Completion: 9 Jan 2030
Last update posted: 30 Jul 2026
Registered enrollment: 5,700
Registry id: NCT07517263

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-519870-38-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.